SG Americas Securities LLC lifted its stake in Cerus Co. (NASDAQ:CERS) by 27.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 126,436 shares of the biotechnology company’s stock after buying an additional 27,204 shares during the quarter. SG Americas Securities LLC owned about 0.08% of Cerus worth $834,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Ameritas Investment Partners Inc. grew its holdings in Cerus by 16.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 12,550 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 1,812 shares in the last quarter. SeaCrest Wealth Management LLC boosted its holdings in shares of Cerus by 9.7% in the 1st quarter. SeaCrest Wealth Management LLC now owns 22,600 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 2,000 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of Cerus by 6.8% in the 1st quarter. Envestnet Asset Management Inc. now owns 32,848 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 2,094 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Cerus by 6.0% in the 1st quarter. Principal Financial Group Inc. now owns 42,750 shares of the biotechnology company’s stock worth $199,000 after purchasing an additional 2,434 shares during the period. Finally, Partnervest Advisory Services LLC boosted its holdings in shares of Cerus by 13.2% in the 1st quarter. Partnervest Advisory Services LLC now owns 25,683 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 3,000 shares during the period. 80.07% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CERS stock opened at $7.13 on Friday. Cerus Co. has a 52-week low of $2.71 and a 52-week high of $7.49. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.47 and a current ratio of 3.95. The firm has a market capitalization of $1.17 billion, a P/E ratio of -14.85 and a beta of 1.29. The stock has a 50 day moving average price of $6.64 and a 200 day moving average price of $5.41.
A number of equities analysts have recently commented on CERS shares. Zacks Investment Research cut Cerus from a “buy” rating to a “hold” rating in a report on Thursday, June 18th. Stifel Nicolaus lifted their target price on Cerus from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 27th. BidaskClub cut Cerus from a “buy” rating to a “hold” rating in a report on Saturday, July 11th. Cantor Fitzgerald initiated coverage on Cerus in a research note on Monday, June 15th. They set a “buy” rating and a $9.00 price target for the company. Finally, Stephens decreased their price target on Cerus from $7.50 to $6.50 and set an “overweight” rating for the company in a research note on Thursday, April 16th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Cerus has a consensus rating of “Buy” and an average price target of $7.40.
In other Cerus news, insider Chrystal Menard sold 20,351 shares of Cerus stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $5.67, for a total transaction of $115,390.17. Following the completion of the sale, the insider now directly owns 72,206 shares of the company’s stock, valued at approximately $409,408.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Carol Moore sold 130,000 shares of Cerus stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $7.00, for a total value of $910,000.00. Following the sale, the senior vice president now directly owns 241,751 shares of the company’s stock, valued at $1,692,257. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 334,959 shares of company stock valued at $2,333,550. 7.26% of the stock is currently owned by corporate insiders.
Cerus Company Profile
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Recommended Story: Coverage Ratio
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.